Online Adaptive stereotactic radiotherapy for abdominopelvic lymphnode oligometastasis.
- Conditions
- abdominopelvic lymphnode oligometastasis10027476
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 53
* Indication to SBRT after discussion in Institutional Tumor Board
* Patients with abdominal and/or pelvic lymph node metastases of solid tumors
* No more than 5 metastatic lesions in no more than 2 organs and a controlled primary tumor site
* Diagnostic imaging includes at least a PET-scan and CT *thorax/abdomen, of which one is not older than 4 weeks at the time of referral for SBRT.
* Primary tumor must be treated at least 4 months before the diagnosis of the metastasis
* Patients must be 18 years or older
* Prior radiotherapy in the same field.
* Second primary malignancy except in situ carcinoma of the cervix, adequately
treated non-melanoma skin cancer, or other malignancy treated at least 3 years
previously without evidence of recurrence.
* Pregnancy.
* Serious concomitant systemic disorders that would compromise the safety of the
patient or his/her ability to complete the study, at the discretion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Determine local control of Stereotactic radiotherapy treatment in patients with<br /><br>abdominal and pelvic lymph node oligometastases.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Determine overall survival<br /><br><br /><br>Toxicity of treatment ( NCI CTCAE). </p><br>